AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3881294 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Ethinylestradiol (EE) for 5 consecutive days
Number of subjects: 493
Study 3881294 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms Ethinylestradiol (EE) and 2 mg dl‐norgestrel (NG)
Number of subjects: 493
Study 30755638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DPIM trays (3D-printed trays with inner marginal-band tissue stops)
Number of subjects: 6
Study 30755638 — intervention group
Group type: COMPARATOR
Intervention: 3DP trays (3D-printed trays without tissue stops)
Number of subjects: 6
Study 30755638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DPS trays (3D-printed trays with saddle-shaped tissue stops)
Number of subjects: 6
Study 30755638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DPM trays (3D-printed trays with marginal-band tissue stops)
Number of subjects: 6
Study 29419896 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer lamp (twice weekly)
Number of subjects: 36
Study 29419896 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol-clobetasol combination (once daily)
Number of subjects: 36
Study 29419896 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer lamp
Number of subjects: 36
Study 29419896 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol-clobetasol combination
Number of subjects: 36
Study 27563091 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mechanism combining free provision of chlorine solution with household vouchers that need to be redeemed monthly.
Number of subjects: 0
Study 27563091 — intervention group
Group type: COMPARATOR
Intervention: Nonvoucher free distribution program (Control).
Number of subjects: 0
Study 24858151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single visit root canal treatment
Number of subjects: 120
Study 24858151 — intervention group
Group type: COMPARATOR
Intervention: Multi visit root canal treatment
Number of subjects: 120
Study 22138361 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Bifidobacterium longum BB536 (BB536Y group) for 8 weeks
Number of subjects: 32
Study 22138361 — intervention group
Group type: COMPARATOR
Intervention: Milk (control group)
Number of subjects: 32
Study 20566266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pre-notification and follow-up
Number of subjects: 880
Study 20566266 — intervention group
Group type: COMPARATOR
Intervention: Pre-notification only
Number of subjects: 880
Study 20566266 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 880
Study 18036451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg twice per day
Number of subjects: 46
Study 18036451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15826716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol 60 g/day
Number of subjects: 75
Study 15826716 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 75
Study 15826716 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath approach
Number of subjects: 40
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Performance Monitor (BPM) feedback training
Number of subjects: 40
Study 12392332 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 40
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific reach training
Number of subjects: 40
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: BPM training group
Number of subjects: 40
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific reach group
Number of subjects: 40
Study 12392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath group
Number of subjects: 40
Study 12392332 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 40
Study 9893073 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (6 months)
Number of subjects: 250
Study 9893073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 250
Study 7776087 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale Observation Scale (YOS) score > 10
Number of subjects: 6611
Study 7776087 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale Observation Scale (YOS) score
Number of subjects: 6611
Study 2185404 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 X 8 mg/d)
Number of subjects: 393
Study 2185404 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (3 X 20 mg/d) and acetylsalicylic acid (1 X 500 mg/d)
Number of subjects: 393
Study 2185404 — intervention group
Group type: EXPERIMENTAL
Intervention: SIN‐I (0.5 mg)
Number of subjects: 393
Study 6113802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg by intramuscular injection one hour before surgery
Number of subjects: 50
Study 6113802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cimetidine)
Number of subjects: 50
Study 31396203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemphigus patients
Number of subjects: 1985
Study 31396203 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1985
Study 31396203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemphigus patients in the 1st year post-diagnosis
Number of subjects: 1985
Study 31396203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemphigus patients managed with systemic medications
Number of subjects: 1985
Study 28346569 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x100,000 IU cholecalciferol every 2 weeks (treatment group)
Number of subjects: 111
Study 28346569 — intervention group
Group type: COMPARATOR
Intervention: Individualized regimen according to baseline 25(OH)VitD level (control group)
Number of subjects: 111
Study 26519165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational intervention
Number of subjects: 58
Study 26519165 — intervention group
Group type: COMPARATOR
Intervention: Didactic educational intervention
Number of subjects: 58
Study 23523254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan (5 mg/h during surgery and up to 24 hours afterwards at 1 mg/h)
Number of subjects: 274
Study 23523254 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 274
Study 20938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy 7 days a week (p-CAIR)
Number of subjects: 279
Study 20938670 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy 5 days a week (CF)
Number of subjects: 279
Study 19627359 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-coated with Clearfil Tri-S Bond
Number of subjects: 2
Study 19627359 — intervention group
Group type: COMPARATOR
Intervention: Non-coated (control)
Number of subjects: 2
Study 17076605 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser technique
Number of subjects: 40
Study 17076605 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (scalpel)
Number of subjects: 40
Study 15025607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino (CBR)
Number of subjects: 53
Study 15025607 — intervention group
Group type: COMPARATOR
Intervention: Guide Wire Dilating Forceps (GWDF)
Number of subjects: 53
Study 11318966 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose warfarin (1 mg/day)
Number of subjects: 105
Study 11318966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 11318966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin (<10.5 g/dL)
Number of subjects: 105
Study 11318966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low international normalized ratio (<1.00)
Number of subjects: 105
Study 11318966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 105
Study 9398954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 38
Study 9398954 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 38
Study 18415463 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac
Number of subjects: 112
Study 18415463 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg apazone
Number of subjects: 112
Study 18415463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 75 mg diclofenac and 600 mg apazone
Number of subjects: 112
Study 18415463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml NaCl 0.9%)
Number of subjects: 112
Study 3365857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose food allergen intake (one egg and one litre of milk daily)
Number of subjects: 165
Study 3365857 — intervention group
Group type: COMPARATOR
Intervention: Low-dose food allergen intake (diet free from hens' egg and cows' milk)
Number of subjects: 165
Study 3365857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet (varied diets)
Number of subjects: 165
Study 29698111 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA) supplementation, 1.5 g/day for 4 weeks
Number of subjects: 19
Study 29698111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn-soy oil)
Number of subjects: 19
Study 27430267 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 588
Study 27430267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 24754607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 0
Study 24754607 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 0
Study 23750963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) in anatomically incongruent condition (hands-parallel/feet-crossed)
Number of subjects: 0
Study 23750963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) with feet active
Number of subjects: 0
Study 23750963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) with complex movement sequence
Number of subjects: 0
Study 23750963 — intervention group
Group type: COMPARATOR
Intervention: Object-touch (not specified)
Number of subjects: 0
Study 20023603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 924
Study 20023603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 924
Study 18494813 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 610
Study 18494813 — intervention group
Group type: COMPARATOR
Intervention: Non-self-monitoring of blood glucose (non-SMBG)
Number of subjects: 610
Study 17048434 — intervention group
Group type: COMPARATOR
Intervention: ZDV + ddI
Number of subjects: 55
Study 17048434 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV + ddI + CHQ
Number of subjects: 55
Study 17048434 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV + ddI (experienced children) + CHQ
Number of subjects: 55
Study 12946037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt intake (energy-adjusted quintiles)
Number of subjects: 120852
Study 12946037 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt added at the hot meal
Number of subjects: 120852
Study 12946037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacon consumption
Number of subjects: 120852
Study 12946037 — intervention group
Group type: EXPERIMENTAL
Intervention: Other sliced cold meat consumption
Number of subjects: 120852
Study 12946037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt and cured meat intake among subjects with self-reported stomach disorders
Number of subjects: 120852
Study 11133338 — intervention group
Group type: EXPERIMENTAL
Intervention: $2 cash incentive
Number of subjects: 4200
Study 11133338 — intervention group
Group type: EXPERIMENTAL
Intervention: $15 cash incentive
Number of subjects: 4200
Study 11133338 — intervention group
Group type: EXPERIMENTAL
Intervention: $200 prize drawing incentive
Number of subjects: 4200
Study 11133338 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 4200
Study 11133338 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives (combined)
Number of subjects: 4200
Study 9062526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester
Number of subjects: 8
Study 9062526 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 8
Study 9062526 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 8230265 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.2 mg, 4 x 10(6) units) once a day, subcutaneously, for 6 months
Number of subjects: 100
Study 8230265 — intervention group
Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 100
Study 3777908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ciprofloxacin (200 mg)
Number of subjects: 12
Study 3777908 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of ciprofloxacin (200 mg)
Number of subjects: 12
Study 3777908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and intravenous administration of ciprofloxacin
Number of subjects: 12
Study 31950482 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (P group)
Number of subjects: 52
Study 31950482 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (S group)
Number of subjects: 52
Study 29122559 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 10
Study 29122559 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Cerbomed Nemos®)
Number of subjects: 10
Study 27565897 — intervention group
Group type: EXPERIMENTAL
Intervention: AL + PQ (artemether-lumefantrine plus primaquine 0.25 mg/kg)
Number of subjects: 220
Study 27565897 — intervention group
Group type: COMPARATOR
Intervention: AL (artemether-lumefantrine alone)
Number of subjects: 220
Study 27565897 — intervention group
Group type: EXPERIMENTAL
Intervention: AL + PQ
Number of subjects: 220
Study 27565897 — intervention group
Group type: COMPARATOR
Intervention: AL
Number of subjects: 220
Study 25040945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day, 6 weeks)
Number of subjects: 47
Study 25040945 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 47
Study 25040945 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic subjects)
Number of subjects: 47
Study 22314053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit & Veg $ense sessions and newsletters at weeks 2 and 5
Number of subjects: 292
Study 22314053 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 292
Study 22314053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit & Veg $ense sessions
Number of subjects: 292
Study 20689074 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐681323, 7.5 mg daily for 28 days, starting 3 days before PCI
Number of subjects: 92
Study 20689074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 18296829 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 57
Study 18296829 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 57
Study 18296829 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 16491814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose doxycycline (20 mg, twice a day)
Number of subjects: 150
Study 16491814 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose doxycycline (200 mg, twice a day)
Number of subjects: 150
Study 16491814 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 150
Study 12397267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (propofol 4.8 mg and alfentanil 12 microg per bolus, no loading dose, lockout time set at zero)
Number of subjects: 100
Study 12397267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation (diazemuls 0.1 mg/kg and meperidine 0.5 mg/kg, with further increases at the discretion of the endoscopist)
Number of subjects: 100
Study 12397267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation
Number of subjects: 100
Study 12397267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 100
Study 10325265 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 115
Study 8649053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines (ANT)
Number of subjects: 0
Study 8649053 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR)
Number of subjects: 0
Study 8649053 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dose-intensive ANT consolidation program
Number of subjects: 0
Study 1960378 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (90 million units per m2 total dose over 12 weeks)
Number of subjects: 114
Study 1960378 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 114
Study 7041145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandaged for three weeks
Number of subjects: 169
Study 7041145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandaged for six weeks (rebandaged after three weeks)
Number of subjects: 169
Study 30946704 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 0.5 to 3 mg/d (flexible dose) adjunct to current antidepressant treatment
Number of subjects: 2944
Study 29939770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (C: 1 g/day, E: 400 IU/day)
Number of subjects: 42
Study 29939770 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 42
Study 29939770 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 26846283 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate subcutaneous (MTX SC)
Number of subjects: 0
Study 26846283 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate oral (MTX OR)
Number of subjects: 0
Study 24717626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily for 12 weeks
Number of subjects: 120
Study 24717626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24717626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily
Number of subjects: 120
Study 22206073 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide/glycerin body moisturizers
Number of subjects: 121
Study 22206073 — intervention group
Group type: EXPERIMENTAL
Intervention: Other moisturizers
Number of subjects: 121
Study 22206073 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 121
Study 20175345 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 72
Study 20175345 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 placebo
Number of subjects: 72
Study 17431725 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colonic J-pouch reconstruction
Number of subjects: 48
Study 17431725 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic straight end-to-end anastomosis
Number of subjects: 48
Study 14998964 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 zygote transfer
Number of subjects: 254
Study 14998964 — intervention group
Group type: COMPARATOR
Intervention: Day 3 cleavage stage embryo transfer
Number of subjects: 254
Study 12495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (n = 1114)
Number of subjects: 757
Study 12495392 — intervention group
Group type: COMPARATOR
Intervention: Early conservative strategy (n = 1106)
Number of subjects: 757
Study 9614605 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST) with intensive management
Number of subjects: 65
Study 9614605 — intervention group
Group type: COMPARATOR
Intervention: Intensive management without CST
Number of subjects: 65
Study 8608069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine (1.5-2 mg with a lockout of 5-10 minutes on demand)
Number of subjects: 67
Study 8608069 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) morphine injection (0.15-0.2 mg/kg every 4 hours on demand)
Number of subjects: 67
Study 8608069 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay following cholecystectomy
Number of subjects: 67
Study 8608069 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay following laminectomy
Number of subjects: 67
Study 2510262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 36
Study 2510262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 36
Study 2510262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 799979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline (204 mg, two capsules twice daily)
Number of subjects: 132
Study 799979 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (250 mg, three times daily)
Number of subjects: 132
Study 30689901 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of intrauterine contraception
Number of subjects: 100
Study 30689901 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study 28592276 — intervention group
Group type: EXPERIMENTAL
Intervention: No mechanical ventilation during cardiopulmonary bypass
Number of subjects: 870
Study 28592276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cmH2O during cardiopulmonary bypass
Number of subjects: 870
Study 28592276 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate of 5 acts/min with tidal volume of 2-3 ml/Kg of ideal body weight and positive end-expiratory pressure of 3-5 cmH2O during cardiopulmonary bypass
Number of subjects: 870
Study 28592276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 870
Study 26390920 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 156
Study 26390920 — intervention group
Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser treatment (HSML)
Number of subjects: 156